Overview

Efficacy and Safety of Iota-Carrageenan Eye Drops (NCX-4240)

Status:
Withdrawn
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
This clinical investigation aims at demonstrating that NCX-4240 is effective and safe in decreasing the number of days where adenoviral conjunctivis is detected in the eye and in reducing the duration and/or the severity of the signs and symptoms of adenoviral conjunctivis
Phase:
Phase 2
Details
Lead Sponsor:
NicOx
Collaborators:
Iris Pharma
Theradis pharma
Treatments:
Carboxymethylcellulose Sodium
Ophthalmic Solutions
Tetrahydrozoline